CSNK1A1 and myelodysplastic syndrome: In 2015, a study by Kronke et al., identified CK1α as a lenalidomide target in myeloid cells and found that heterozygous deletion of CSNK1A1 in del(5q) MDS provides a therapeutic window for selective targeting of the malignant cells [63].